Immune cells in cancer
Immune cells in cancer is a research topic within Immunology. Science Explorer counts 39k research works in it since 1951. 29.8% of them reached the world's top 10% most cited for their field and year.
This cluster of papers explores the diverse aspects of macrophage activation and polarization, including their role in tumor microenvironments, interaction with myeloid-derived suppressor cells, modulation of immune responses, and metabolic regulation. The papers cover topics such as monocyte and macrophage heterogeneity, tissue-resident macrophages, and the impact of macrophage plasticity on health and disease.
- Macrophage
- Activation
- Polarization
- Tumor-associated
- Monocytes
- Myeloid-derived suppressor cells
- Inflammation
- Metabolism
- Cancer
- Immunity
- Research works
- 39k fractional, since 1951
- In the world top 10%
- 12k per year above
- Top-10% rate
- 29.8% share of its works in the world top 10%
- Growth, 2013–17 → 2018–22
- +76% the tick is no change
Which countries lead Immune cells in cancer research?
By volume, China and the United States publish the most (5.9k and 2.6k works in 2022–2025).
By volume, 2022–2025
- 1 China 5.9k works
- 2 United States 2.6k works
- 3 Germany 461 works
- 4 Japan 389 works
- 5 United Kingdom 292 works
- 6 South Korea 277 works
- 7 Italy 255 works
- 8 France 234 works
- 9 India 216 works
- 10 Canada 199 works
How concentrated that is
The same countries as shares of everything the list above accounts for. A node where two countries do two thirds of the work and one spread evenly across twelve read alike as a ranking and not at all alike here.
Shares of the rows listed above, not of the whole node.
Which institutions lead Immune cells in cancer research?
By volume in 2022–2025, Sun Yat-sen University publishes the most Immune cells in cancer research, followed by Chinese Academy of Medical Sciences & Peking Union Medical College and Shanghai Jiao Tong University.
By volume, 2022–2025
- 1 Sun Yat-sen UniversityChina 105 works
- 2 Chinese Academy of Medical Sciences & Peking Union Medical CollegeChina 94 works
- 3 Shanghai Jiao Tong UniversityChina 82 works
- 4 Sichuan UniversityChina 72 works
- 5 Nanjing Medical UniversityChina 71 works
- 6 Huazhong University of Science and TechnologyChina 67 works
- 7 The University of Texas MD Anderson Cancer CenterUnited States 61 works
- 8 Central South UniversityChina 60 works
- 9 Fudan UniversityChina 57 works
- 10 Southern Medical UniversityChina 56 works
Who are the leading researchers in Immune cells in cancer?
The most-cited researchers publishing on Immune cells in cancer include Guido Kroemer.
- 1 Guido Kroemer France 4.2k citations
Ranked by citations received across their whole record, among researchers with at least three works on this topic.
Where is Immune cells in cancer research done?
The largest centres of Immune cells in cancer research in 2022–2025 are Shanghai (China), Beijing (China), Guangzhou (China) and Nanjing (China). Among places with at least 20 works in it, it is an unusually large share of all research in Luzhou, Shatin and Nantong.
Largest cities, 2022–2025
Where it is the local speciality
- LuzhouCN · 33.0 works11×
- ShatinCN · 27.4 works9.6×
- NantongCN · 40.0 works7.1×
- XuzhouCN · 28.3 works6.8×
Location quotient: how much more of its research is in Immune cells in cancer than the world average.
Where is the best place to study Immune cells in cancer?
Among universities, judged by research, Southern Medical University, Chinese Academy of Medical Sciences & Peking Union Medical College and Nanjing University of Chinese Medicine score highest, combining excellence, specialisation, size, growth and international reach. Research strength is one signal when choosing where to study; it does not measure teaching.
One dot per university in the table below. The upper left is the interesting corner: small places doing unusually strong work.
| # | University | Score | Top 10% | Specialisation | Works | Growth |
|---|---|---|---|---|---|---|
| 1 | Southern Medical UniversityChina | 80.8 | 47.3% | 12.9× | 56 | +210.0% |
| 2 | Chinese Academy of Medical Sciences & Peking Union Medical CollegeChina | 76.4 | 44.4% | 8.1× | 94 | +167.8% |
| 3 | Nanjing University of Chinese MedicineChina | 75.9 | 45.2% | 12.9× | 39 | +490.1% |
| 4 | Nanjing Medical UniversityChina | 75.6 | 38.2% | 11.6× | 71 | +169.1% |
| 5 | China Pharmaceutical UniversityChina | 72.8 | 40.2% | 13.3× | 34 | +357.4% |
| 6 | Guangzhou Medical UniversityChina | 72.5 | 37.0% | 11.2× | 36 | +202.6% |
| 7 | Zhejiang Chinese Medical UniversityChina | 72.0 | 39.4% | 11.4× | 35 | +251.0% |
| 8 | China Medical UniversityChina | 71.3 | 45.0% | 11.9× | 46 | +102.9% |
| 9 | Anhui Medical UniversityChina | 68.8 | 36.9% | 10.3× | 37 | +157.5% |
| 10 | Dalian Medical UniversityChina | 68.7 | 39.7% | 11.1× | 25 | +179.0% |
Universities only. Score blends excellence (30%), specialisation (25%), size (20%), growth (15%) and international reach (10%), 2015–2022; growth compares 2010–14 with 2015–19.
Is Immune cells in cancer research growing?
Output in 2018–2022 was 76% higher than in 2013–2017, peaking in 2025. The fastest-growing topics are Immune cells in cancer.
The same series as a ribbon — one cell per year, darker for more. The line above answers how much; this answers when.
Which topics inside it are moving
Growth and decline on one axis around a shared zero. Two lists side by side hide the thing that matters: whether the growth dwarfs the decline, or the other way round.